Last-minute discussions between the NHIS and the pharmaceutical industry are underway regarding PVA of cold medicines, which increased their use due to COVID-19 last year. The consultation began when the government decided to correct the usage instead when the pharmaceutical industry suggested that cold medicines, which have increased their usage due to COVID-19, should be excluded from the PVA. The issue is how far we look at a specific time when usage increased due to COVID-19 last year. This is because the longer the correction time, the more advantageous it is for the pharmaceutical industry, and the shorter the correction effect.

The PVA of cold medicines, which are mostly generic drugs, compares